AstraZeneca announced that the FDA has approved rosuvastatin to reduce total cholesterol, LDL and apolipoprotein B in pediatric patients aged 8 to 17 years with heterozygous familial hypercholesterolemia.
According to the company, rosuvastatin (Crestor, AstraZeneca) can now be administered to that patient population after failure of an adequate-length attempt at control through diet if LDL > 190 mg/dL or if LDL > 160 mg/dL and the patient has a family history of CVD or at least two other risk factors for CVD.
This activity is supported by an educational grant from Merck & Co., Inc.
This activity is supported by an educational grant from Salix, A Dvision of Valeant Pharmaceuticals North America, LLC.
New technologies advance treatment options for patients with arrhythmia disorders, HF
A look at ezetimibe and the IMPROVE-IT trial
PCSK9 inhibitors change treatment approach for dyslipidemia
This feature offers timely executive summaries of the most relevant journals in cardiology.
Snapshot summaries of recent study results in cardiology.
Your central portal for information presented at ACC 2015.
Your resource for news and videos from SCAI 2014.
This exclusive Healio resource provides you a comprehensive window into what your colleagues and key opinion leaders are saying about current and future drugs and devices and their impact on patient outcomes.
Related story »
View past polls »
Search Healio's robust listing of national and international medical meetings.
©2015 All Rights Reserved.